Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial

This article was originally published here

The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of

The post Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply